Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
Cue Biopharma (Nasdaq: CUE), a clinical-stage biopharmaceutical company, announced its participation in a fireside discussion at the Piper Sandler 36th Annual Healthcare Conference in New York, NY, from December 3-5, 2024. The company will present updates on clinical and preclinical programs, along with strategic business and partnering objectives.
The presentation will be delivered by CEO Daniel Passeri on Wednesday, December 4, 2024, from 9:00 AM to 9:25 AM EST. A live webcast will be available, and the recording will be archived for 30 days on the company's website.
Cue Biopharma (Nasdaq: CUE), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione a una discussione informale durante il Piper Sandler 36° Annual Healthcare Conference a New York, NY, dal 3 al 5 dicembre 2024. L'azienda presenterà aggiornamenti sui programmi clinici e preclinici, insieme agli obiettivi strategici di business e di partnership.
La presentazione sarà a cura del CEO Daniel Passeri il mercoledì 4 dicembre 2024, dalle 9:00 alle 9:25 EST. Sarà disponibile una diretta web, e la registrazione sarà archiviata per 30 giorni sul sito web dell'azienda.
Cue Biopharma (Nasdaq: CUE), una empresa biofarmacéutica en etapa clínica, anunció su participación en una discusión informal en la Piper Sandler 36ª Conferencia Anual de Salud en Nueva York, NY, del 3 al 5 de diciembre de 2024. La empresa presentará actualizaciones sobre programas clínicos y preclínicos, así como sobre objetivos estratégicos de negocio y asociaciones.
La presentación será realizada por el CEO Daniel Passeri el miércoles 4 de diciembre de 2024, de 9:00 AM a 9:25 AM EST. Se dispondrá de una transmisión en vivo, y la grabación se archivará durante 30 días en el sitio web de la empresa.
Cue Biopharma (Nasdaq: CUE), 임상 단계의 바이오제약 회사가 뉴욕 NY에서 2024년 12월 3일부터 5일까지 열리는 Piper Sandler 제36회 연례 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 이 회사는 임상 및 비임상 프로그램에 대한 업데이트와 함께 전략적 비즈니스 및 파트너십 목표를 발표할 예정입니다.
프레젠테이션은 2024년 12월 4일 수요일 오전 9시부터 9시 25분(EST)까지 CEO 다니엘 파세리(Daniel Passeri)에 의해 진행됩니다. 실시간 웹캐스트가 제공되며, 녹화된 내용은 회사 웹사이트에 30일간 보관됩니다.
Cue Biopharma (Nasdaq: CUE), une entreprise bio-pharmaceutique en phase clinique, a annoncé sa participation à une discussion informelle lors de la Piper Sandler 36ème Conférence Annuelle sur la Santé à New York, NY, du 3 au 5 décembre 2024. L'entreprise présentera des mises à jour sur ses programmes cliniques et précliniques, ainsi que sur ses objectifs stratégiques de partenariat et d'affaires.
La présentation sera faite par le CEO Daniel Passeri le mercredi 4 décembre 2024, de 9h00 à 9h25 EST. Un webinaire en direct sera disponible, et l'enregistrement sera archivé pendant 30 jours sur le site web de l'entreprise.
Cue Biopharma (Nasdaq: CUE), ein biopharmazeutisches Unternehmen in der klinischen Phase, gab seine Teilnahme an einer informellen Diskussion auf der Piper Sandler 36. jährlichen Gesundheitskonferenz in New York, NY, vom 3. bis 5. Dezember 2024, bekannt. Das Unternehmen wird Neuigkeiten zu klinischen und präklinischen Programmen sowie zu strategischen Geschäftszielen und Partnerschaften präsentieren.
Die Präsentation wird am Mittwoch, den 4. Dezember 2024, von 9:00 bis 9:25 Uhr EST von CEO Daniel Passeri gehalten. Ein Live-Webcast wird verfügbar sein, und die Aufzeichnung wird 30 Tage lang auf der Unternehmenswebsite archiviert.
- None.
- None.
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY, Dec 3-5, 2024.
During the fireside discussion, Cue Biopharma will provide an overview highlighting recent clinical and preclinical program updates as well as strategic business and partnering model objectives.
Presentation Details
Date and Time: Wednesday, December 4, 2024, from 9 a.m. EST – 9:25 a.m. EST
Webcast Link: https://event.webcasts.com/starthere.jsp?ei=1697351&tp_key=a82c532edc
Presenter: Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma
A live and archived webcast of the fireside discussion will be available on the Events page in the Investors and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
FAQ
When is Cue Biopharma (CUE) presenting at the Piper Sandler Healthcare Conference 2024?
What will Cue Biopharma (CUE) discuss at the Piper Sandler Conference 2024?
How can investors watch Cue Biopharma's (CUE) presentation at the Piper Sandler Conference?
